認識腎細胞癌

Urology Division of Taipei Veteran General Hospital

*


(Cortex)(Medulla)

*


(Nephron) (Renal Corpuscle)(Renal Tubule) *


*


(Collecting Duct System) *


(Renal Cell Carcinoma)8085Classic Triad:(Hematuria)(Flank pain) (Abdominal mass) *


In 2006, 63,000 new cases in EUIn 2006, 39,000 new cases in United StatesAge-standardized incidence rate per 100,000


Urology Division of Taipei Veteran General Hospital*


2003200420052006200762864673374379827%60


Chart2

403225

407239

479254

474269

522276

Sheet1

2003403225

2004407239

2005479254

2006474269

2007522276

Sheet1

00

00

00

00

00

Sheet2

Sheet3

6~10% 20~30%


(: 2006 )


: : : , , (VHL) ( 3p Deletion) : ,, : Urology Division of Taipei Veteran General Hospital*


10-15%60%40%30%


(ultrasound) 98%(CT scan) IVU


(magnetic resonance imaging MRI)


(angiogram) (radionuclide imaging) x alkaline phosphatase


*


*Type Clear cell Papillary type 1 Papillary type 2 Chromophobe Oncocytoma

ApproximateIncidence 75% 5% 10% 5% 5%

Associated VHL c-Met FHBHD BHDmutationsClear Cell 75%Non Clear Cell 25%


*


Five-year relative survival rates by tumor stage at diagnosis based on cases diagnosed during 19921999, followed through 2000. Drucker BJ. Cancer Treat Rev. 2005;31:536.


Surgery (Radical or partial nephrectomy )Targeted therapyImmunotherapyRadiation therapyChemotherapyCryosurgery Radiofrequency ablation (RFA)


75~95% 0~5%


(38.5) 150~200CC() (5)


()()


: X-


-interferon-(IL-2)15-20%


*Avastin + IFN()Sutent()Torisel()Afinitor ()Nexavar()Inlyta ()


mTOR500


Thanks For Your Attention !! *


**Renal cancer makes up approximately 2%3% of all cancers, and the burden of disease is significant.1[Ferlay2007, 587table 5]2[Bellmunt2009, 572a]Click to bring up each point on screen. In 2006 there were 63,000 new cases of renal cancer diagnosed in the European Union (EU), and 26,000 people died from the disease.1[Ferlay2007, 587table 5, 588table 6]During the same year, 39,000 new cases were diagnosed in the United States, resulting in 13,000 deaths.3[Jemal2006, 107table 1]

The image displayed on this slide is a map of the incidence of kidney cancer in men from the GLOBOCAN 2002 database. The incidence rates are agestandardized, and rates are displayed per 100,000 individuals.

References:Ferlay J, Autier P, Boniol M, et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007;18(3):581-592.Bellmunt J, Guix M. The medical management of metastatic renal cell carcinoma: integrating new guidelines and recommendations. BJU Int. 2009;103(5):572-577.Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56(2):106-130.GCT6467*After completing this presentation, participants will be able to:List the key findings of preclinical, phase 1, and phase 2 studies of everolimus.Describe the methods and efficacy and safety results of the RECORD1 study.GCT6467*After completing this presentation, participants will be able to:List the key findings of preclinical, phase 1, and phase 2 studies of everolimus.Describe the methods and efficacy and safety results of the RECORD1 study.GCT6467*After completing this presentation, participants will be able to:List the key findings of preclinical, phase 1, and phase 2 studies of everolimus.Describe the methods and efficacy and safety results of the RECORD1 study.GCT6467*After completing this presentation, participants will be able to:List the key findings of preclinical, phase 1, and phase 2 studies of everolimus.Describe the methods and efficacy and safety results of the RECORD1 study.*GCT6467*After completing this presentation, participants will be able to:List the key findings of preclinical, phase 1, and phase 2 studies of everolimus.Describe the methods and efficacy and safety results of the RECORD1 study.GCT6467*After completing this presentation, participants will be able to:List the key findings of preclinical, phase 1, and phase 2 studies of everolimus.Describe the methods and efficacy and safety results of the RECORD1 study.GCT6467*

Documents

認識腎細胞癌